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This population-based study evaluates the impact of a strong family history of breast cancer on management and survival of women
with early-onset disease. We identified all breast cancer patients p50 years, recorded between 1990 and 2001 at the Geneva familial
breast cancer registry. We compared patients at high familial risk and low familial risk in terms of tumour characteristics, method
of detection, treatment, survival and breast cancer mortality risk. Compared to patients at low familial risk (n¼575), those at
high familial risk (n¼58) received significantly more often systemic therapy, especially for node-negative or receptor-positive disease.
Five-year disease-specific survival rates of patients at high vs low familial risk were 86 and 90%, respectively. After adjustment, there
was no difference in breast cancer mortality in general. A strong family history nonsignificantly increased breast cancer mortality in
patients p40 years (adjusted hazard ratio (HR) 4.0, 95% CI 0.8–19.7) and in patients treated without chemotherapy (adjusted HR
2.7, 95% CI 0.6–12.5). A strong family history of breast cancer is associated with an increased use of systemic therapy in early-onset
patients. Although a strong family history does not seem to affect survival in general, it may impair survival of very young patients and
patients treated without adjuvant chemotherapy. Owing to the limited number of patients in this study, these results should be used
only to generate hypotheses.
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One of the most important risk factors for breast cancer is the
occurrence of breast or ovarian cancer among family members.
Women with one or more first-degree relatives with breast cancer
have a 1.8–3.0-fold increased risk of developing the disease
(Pharoah et al, 1997; Collaborative Group on Hormonal Factors in
Breast Cancer, 2001). Nevertheless, only about 5–10% of breast
cancer patients carry a genetic predisposition to breast and/or
ovarian cancer due to a highly penetrant germline mutation
(Narod and Foulkes, 2004).
Some asymptomatic women carrying germline mutations in
BRCA1 or BRCA2 genes undergo prophylactic bilateral mastect-
omy and/or salpingo-oophorectomy to reduce their risk of
developing breast and/or ovarian cancer (Meijers-Heijboer et al,
2001; Stefanek et al, 2001; Rebbeck et al, 2002). Others are offered
periodic clinical examination and breast imaging (mammography,
ultrasound and magnetic resonance imaging). For unaffected
women with an unknown or noninformative mutation status, but
with a strong family history of breast cancer, intensive surveillance
is also highly recommended (Pichert et al, 2003), as it may lead to
earlier detection of breast cancer in a more favourable stage
(Eccles et al, 2000; Tilanus-Linthorst et al, 2000).
Treatment guidelines of breast cancer occurring in BRCA1/
BRCA2 mutation carriers or in patients with an increased familial
risk are not well established. The risk of local recurrence does not
appear to be higher among patients with a strong family history
than among low familial risk patients, rendering high familial risk
patients equally eligible for breast-conserving surgery (Eccles et al,
2001; Vlastos et al, 2002; Robson et al, 2004). However, their risk
for contralateral disease is highly increased (Robson et al, 2004).
Conflicting data exist on the impact of a family history of breast
or ovarian cancer on the outcome of breast cancer (Ruder et al,
1988; Chappuis et al, 1999; Russo et al, 2002). Some studies have
shown improved survival rates among breast cancer patients with
affected relatives compared to those without a family history
(Malone et al, 1996; Mohammed et al, 1998), some reported poorer
survival rates (Slattery et al, 1993; Gonzalez-Angulo et al, 2005),
and others did not find any survival difference between patients
with or without a family history (Greenberg et al, 1985; Kinoshita
et al, 2004). Although most of these studies used multivariate
analysis to adjust mortality risks for other prognostic variables,
none of them adjusted for use of systemic therapy.
In this study, we focus on young breast cancer patients. We will
show that, among women with early-onset breast cancer, the
presence of a strong family history does not lead to earlier
diagnosis of the disease. However, family history has a strong
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simpact on the use of systematic therapy. In addition, we will
show that women with a strong family history have similar breast
cancer survival rates as patients with a low familial risk, except for
certain subgroups.
METHODS
We used information from the Geneva cancer registry, which
records all incident cancers occurring in the population of the
Geneva canton (approximately 420000 inhabitants) since 1970.
It collects information from various sources and is considered
accurate, as attested by its very low percentage (o2%) of cases
recorded from death certificates only (Bouchardy, 1997). All
hospitals, pathology laboratories, and private practitioners in the
canton are requested to report all cancer cases. Trained tumour
registrars systematically abstract data from medical and laboratory
records. Physicians regularly receive enquiry forms to complete
missing clinical and therapeutic data. Recorded data include
sociodemographic information, method of diagnosis, type of
confirmation, tumour characteristics coded according to the
International Classification of Diseases for Oncology (World
Health Organization, 1976), stage of disease at diagnosis, hormonal
receptor status and treatment during the first 6 months after
diagnosis. The registry regularly assesses survival, taking as
reference date the date of confirmation of diagnosis or the date
of hospitalisation (if it preceded the diagnosis and was related to
the disease). In addition to passive follow-up (standard examina-
tion of death certificates and hospital records), active follow-up is
performed yearly using the files of the Cantonal Population Office
(office in charge of the registration of the resident population).
Cause of death is taken from clinical files.
In 1999, the Geneva Cancer Registry set up a Familial Breast
Cancer Registry, by extending its data set to the detailed family
history of cancer for all women diagnosed with invasive breast
cancer in the Geneva population (Bouchardy et al, 2002). For
breast cancer patients diagnosed between 1990 and 1999, family
history was collected retrospectively, using information from
medical records from the public university hospitals and private
physicians. For 90% of the breast cancer patients, information on
family history was obtained and the accuracy of this retro-
spectively retrieved information has been validated (Murff et al,
2004; Verkooijen et al, 2004). Since January 2000, family history on
X3 generations is prospectively collected by sending standard
questionnaires to health-care providers.
For the purpose of this study, we classified breast cancer
patients into three familial risk categories according to the number
of relatives diagnosed with breast or ovarian cancer, their age
at diagnosis and their degree of kinship (Hampel et al, 2004). The
low familial risk category included breast cancer patients without
first- or second-degree relatives with breast or ovarian cancer (i.e.
sporadic cases). The high familial risk category included patients
who reported one of the following family histories: (1) X1 first-
degree relative with breast or ovarian cancer p50 years; (2) X2
first-degree relatives with breast/ovarian cancer at any age; (3) X3
cases of breast/ovarian cancer among first- or second-degree
relatives. Patients with other types of family history were classified
into the moderate familial risk category.
We restricted the current study to women with early-onset
breast cancer (p50 years). We excluded patients with a
moderately increased familial risk in order to maximise the
difference in effect of family history. We divided age into two
categories (p40 years, 41–50 years). We categorised method of
detection as due to symptoms (i.e. palpable lump, nipple
discharge, etc.), fortuitously (i.e. during the work-up or treatment
of another unrelated illness), breast self-examination and surveil-
lance (i.e. screening of healthy individuals by means of physical
examination, mammography, ultrasound or MRI).
Socioeconomic status was based on the woman’s last occupation
or, for the unemployed, that of the spouse. Four levels were
considered as follows: low (manual employees, skilled and
unskilled workers), middle (non-manual employees and adminis-
trative staff), high (professionals, executives, administrators) and
unknown. For staging, we used the pathological pTNM (tumour
node metastasis) classification system or, when not available, the
clinical cTNM classification (Sobin and Wittekind, 2002). Tumours
were classified as T1 (p2cm), T2 (2–5cm), T3 (45cm), T4
(invasion to chest wall/skin and inflammatory carcinoma) and TX
(unknown). Axillary lymph node invasion was classified as N0 (no
invasion), or Nþ (including N1 – movable – , N2 – fixed – and NX
– unknown). Distant metastasis was classified as M0 (absent), M1
(present) or MX (unknown). Stage was classified in five groups:
stage I (Tis or T1 and N0), stage II (T0 or T1 and N1, T2 and N0 or
N1, T3 and N0), stage III (T0 or T1 or T2 and N2, T3 and N1 or N2,
T4 and any N, any T and N3), stage IV (M1) and unknown. Tumor
size was categorised as o1, 1–1.9, 2–4.9 and X5cm. Tumour
differentiation (grade) was classified as well differentiated (grade
1), moderately differentiated (grade 2) and poorly differentiated
(grade 3). Oestrogen receptor status was determined by standard
immunohistochemical reaction and considered positive when
X10% of the cancer cells expressed oestrogen receptors.
Locoregional therapy was categorised as breast-conserving
surgery followed by radiotherapy, mastectomy, bilateral mastect-
omy (defined as amputation of both breasts for unilateral
breast cancer) and other (including tumorectomy without radio-
therapy, no surgery). Use of chemotherapy and hormonotherapy
was categorised as yes vs no. Contralateral breast cancer was
categorised as ‘synchronous’ if detected within 6 months after
diagnosis, and ‘metachronous’ if diagnosed later. Information on
BRCA1/BRCA2 status was not routinely available.
Statistics
To compare method of discovery, stage at diagnosis and treatment
between patients at high and low familial risk, we used a case–
control approach. Cases were breast cancer patients with a strong
family history and controls were patients without affected rela-
tives. With unconditional univariate logistic regression analysis,
we identified the factors that were significantly associated with a
high familial risk. With multivariate analyses, we adjusted the
relative risks for all factors significantly associated with family
history in univariate analysis.
We used Kaplan–Meier analysis to calculate breast cancer
survival rates for women at high familial risk and those at low
familial risk. With univariate Cox proportional hazards analysis,
we identified all variables significantly linked to survival. Finally,
we calculated breast cancer mortality risk (hazard ratio, HR) for
patients with a highly increased familial risk compared to those
without a family history, adjusting for all other factors significantly
linked to survival. To evaluate if the effect of familial risk was
different between age groups, we stratified by different age
categories (o41 years, 41–50 years) and tested for interaction.
We also investigated if the use of chemotherapy changed the
effect of a strong family history. Data were analysed with SPSS
software and differences were considered significant at a two-sided
P-value o0.05.
RESULTS
Between 1990 and 2001, 3709 women were diagnosed with invasive
breast cancer in the canton of Geneva. Among them, 824 (22%)
were p50 years of age. A total of 58 (7%) patients reported a
family history classified as high familial risk, 191 (23%) a moderate
familial risk and 575 (70%) reported no first- or second-degree
relatives with breast or ovarian cancer. Patients with a moderate
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sfamilial risk were excluded from further analysis. Details on family
history of the patients in the high familial risk category are
presented in Table 1.
In Table 2, we present the patient and tumour characteristics of
breast cancer patients with high vs low familial risk. There was no
significant difference in age or period of diagnosis. Women with a
strong family history had less frequently stage I disease at
diagnosis (24 vs 36%, P¼0.043), and more often stage III disease
(19 vs 9%, P¼0.014), when compared to low familial risk patients.
After adjustment for age, women at high familial risk were
significantly more likely to be diagnosed with stage III disease than
patients without a family history of breast cancer (adjusted odds
ratio (OR) 3.3, 95% CI 1.4–7.8).
Women at high familial risk tended to have more frequently
axillary lymph node involvement compared to women at low
familial risk (53 vs 43%, respectively), grade 1 tumours (33 vs 23%,
respectively) and oestrogen receptor-positive tumours (74 vs
64%, respectively), but these differences were not statistically
significant.
The risk of presenting synchronous bilateral breast cancer was
increased among patients with a high familial risk (adjusted OR
3.9, 95% CI 1.0–15.8, P¼0.051), while the risk to develop
metachronous contralateral breast cancer was similar for both
groups (median follow-up 5.2 years).
There were no differences in histological subtypes between the
high familial risk and low familial risk groups (data not shown):
81% of low familial risk patients vs 85% of high familial risk
patients had ductal histology, 10% of low and high familial risk
patients lobular histology and 2% of low familial risk vs 0% of high
familial risk patients had medullar histology.
Table 3 shows the methods of tumour detection and manage-
ment of breast cancer according to familial risk. No significant
differences were observed between the high and low familial risk
patients. The proportion of tumours detected by surveillance was
slightly higher among women at high familial risk than those at
low familial risk (28 vs 23%, respectively), but this result was not
significant.
Breast-conserving therapy was performed at a similar rate in
patients at high vs low familial risk. Bilateral mastectomy for
unilateral disease was more common among women with a strong
family history (adjusted OR 4.2, 95% CI 0.9–18.4).
Patients at high familial risk received more often chemotherapy
than low familial risk patients (74 vs 65%, respectively), but this
difference was not significant. A higher proportion of women at
high familial risk received hormonotherapy (57 vs 43% in low
familial risk women, P¼0.013). After adjustment for age, stage,
oestrogen receptor status, locoregional therapy and chemotherapy,
the probability to receive hormonotherapy remained significantly
increased among patients at high familial risk (adjusted OR 1.9,
95% CI: 1.1–3.4).
Table 4 shows the use of systemic therapy according to axillary
lymph node invasion and oestrogen receptor status. In the group
of patients with node-negative disease, those at high familial risk
were more likely to be treated with any type of systemic therapy
(88 vs 65% of low risk women, P¼0.024). The proportion of
women treated with hormonotherapy was also significantly higher
(67 vs 39%, P¼0.007), as was the proportion of women treated
with both hormonotherapy and chemotherapy (38 vs 19%,
P¼0.034). In the group of lymph node-positive patients, high
familial risk patients received equally frequently systemic therapy
as low familial risk patients (94 vs 93%, respectively), but they were
more often treated with both chemotherapy and hormonotherapy
(52 vs 40%, respectively, P¼0.011).
In the group of women with oestrogen receptor-positive
tumours, patients at high familial risk received significantly more
frequently hormonotherapy when compared to patients at low
familial risk (74 vs 56%, respectively, P¼0.020), chemotherapy (77
vs 61%, respectively, P¼0.044) and both (58 vs 38%, respectively,
P¼0.011). In the group of patients with oestrogen receptor-
negative tumours, no significant differences in use of systemic
therapy were observed.
Figure 1 shows the survival rates of women with a high familial
risk and those at low familial risk. At 5 years, the breast cancer-
specific survival of women at high familial risk was 86% (95% CI:
75–97%) compared to 90% (95% CI: 87–93%) for women with
out a family history. At 10 years, survival rates were 82% (95% CI:
69–95%) and 82% (95% CI: 79–87%), respectively.
In univariate analysis, well-known prognostic variables such as
socioeconomic status, stage, histological grade, oestrogen receptor
status, locoregional treatment and chemotherapy proved to be
significantly related to breast cancer-specific survival (data
not shown). Use of hormonotherapy decreased the breast
cancer mortality risk by 40% (HR 0.6, 95% CI: 0.4–1.1), but this
result was not statistically significant. In univariate analysis,
patients with a strong family history did not have an increased
risk of dying of breast cancer compared to patients without
a family history (HR 1.1, 95% CI: 0.5–2.2). After adjustment for
all factors significantly linked to survival in univariate analysis
(including hormonotherapy), the risk of dying of breast cancer
was not significantly different among women at high familial
risk compared to those at low familial risk (adjusted HR 1.3, 95%
CI: 0.6–2.8).
Table 5 presents the breast cancer mortality risks of patients
with a high familial risk compared to those at low familial risk
stratified by age and use of chemotherapy. For women aged 41–50
years, a highly increased familial risk was not associated with
an increased risk to die of breast cancer (HR 1.0, 95% CI: 0.4–2.6).
However, in the category of patients of 40 years or younger,
breast cancer mortality risk was increased for patients at high
familial risk, although not significantly (HR 4.0, 95% CI: 0.8–19.7).
Test for interaction between age and familial risk was also
not significant.
In the subgroup of patients treated with chemotherapy, a strong
family history was not associated with an increased breast cancer
mortality risk (HR 1.0, 95% CI: 0.4–2.6) (Table 5). Among patients
treated without chemotherapy, a strong family history increased
the breast cancer mortality risk, although not significantly (HR 2.7
95% CI: 0.6–12.5). Test for interaction between use of chemo-
therapy and familial risk was not significant either.
Table 1 Description of family history of breast and ovarian cancer
among 58 breast cancer patients diagnosed p50 years and classified as
high familial risk
Family history n¼58
At least one FDR with breast/ovarian cancer p50 years 30
One FDR p50 years with breast cancer (with or without other
relatives with breast cancer)
26
One FDR p50 years with bilateral breast cancer 4
At least two breast/ovarian cancers among FDRs 4
Two FDRs with breast cancer 2
One FDR with bilateral breast cancer and one SDR with breast
cancer
2
At least three cases of breast/ovarian cancer among FDRs or SDRs 24
Two FDRs with ovarian cancer and one FDR with breast cancer 1
One FDR with bilateral breast cancer, two SDRs with breast cancer
and one SDR with ovarian cancer
1
Two relatives with breast cancer and one with ovarian cancer 2
Three relatives with breast cancer 15
Four relatives with breast cancer 3
Five relatives with breast cancer and one with ovarian cancer 1
Six relatives with breast cancer 1
Geneva Cancer Registry 1990–2001. FDR¼first-degree relative: mother, sister(s),
daughter(s). SDR¼second-degree relative: grandmother(s), aunt(s), niece(s).
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sOf the 10 high familial risk women younger than 41 years, two
did not receive systemic therapy. Both of them died within 5 years
after diagnosis.
In the subgroup of patients with poorly differentiated (grade 3)
tumours, a strong family history was not associated with a
significantly increased mortality risk (adjusted HR 1.2, 95% CI
0.4–4.0) (data not shown).
Finally, we analysed the survival of the 191 patients at moderate
familial risk. Their 5 and 10 years specific survival rates were 93%
(95% CI 89–97%) and 85% (95% CI 77–93%), respectively, and
not significantly different than those of low familial risk patients.
Also, the multiadjusted breast cancer mortality risk of patients
with a moderately increased familial risk was not significantly
different than that of patients at low familial risk (HR 0.7, 95% CI
0.4–1.3).
DISCUSSION
In this population-based study, we show that breast tumours
occurring at an early age among women belonging to high-risk
families were neither discovered more frequently by screening or
surveillance nor diagnosed at an earlier stage than in patients
without a family history of breast cancer. However, after the
diagnosis of invasive breast cancer, patients at high familial risk
were treated differently compared to patients without a family
history, particularly regarding the prescription of systemic
therapy. In addition, this study shows that a strong family history
of breast and/or ovarian cancer was not associated with a
decreased survival after early-onset breast cancer, except, maybe,
for very young patients and patients not receiving chemotherapy.
Standard protocols for the surveillance of women carrying
BRCA1/BRCA2 germline mutations become increasingly wide-
spread, but vary from one centre to another (Stefanek et al, 2001;
Eisinger et al, 2004; Warner et al, 2004). For women with
noninformative genetic test results and/or a positive family
history, some screening protocols have been proposed (Pichert
et al, 2003). These protocols could lead to an earlier diagnosis
of breast cancer at even preclinical stages (Tilanus-Linthorst et al,
2000). We were surprised to find that in Geneva, young breast
cancer patients with a strong family history were not diagnosed
Table 2 Patient and tumour characteristics for breast cancer patients at high and low familial risk
High familial
risk (n¼58)
Low familial risk
(n¼575)
Unadjusted OR
(95% CI)
Age- and stage-adjusted
OR (95% CI)
Age category
41–50 years 48 (82%) 441 (77%) 1
a 1
a,b
p40 years 10 (18%) 134 (24%) 0.7 (0.3–1.4) 0.7 (0.3–1.4)
Period of diagnosis
1990–1993 13 (22%) 163 (28%) 1
a 1
a
1994–1997 20 (35%) 201 (35%) 1.2 (0.6–2.6) 1.3 (0.6–2.8)
1998–2001 25 (43%) 211 (37%) 1.5 (0.7–3.0) 1.6 (0.8–3.3)
Stage
Stage I 14 (24%) 208 (36%) 1
a 1
a,c
Stage II 28 (48%) 272 (47%) 1.5 (0.8–3.0) 1.5 (0.8–3.0)
Stage III 11 (19%) 49 (9%) 3.3 (1.4–7.8)** 3.3 (1.4–7.8)**
Stage IV 1 (2%) 30 (5%) 0.5 (0.1–3.9) 0.5 (0.1–3.9)
Unknown 4 (7%) 16 (3%) — —
Tumour size
o1cm 13 (22%) 89 (16%) 1
a 1
a,d
1–1.9cm 16 (28%) 224 (39%) 0.5 (0.2–1.1) 0.4 (0.2–1.0)
2–4.9cm 16 (28%) 166 (29%) 0.7 (0.3–1.4) 0.6 (0.3–1.3)
45cm 4 (7%) 21 (4%) 1.3 (0.4–4.4) 1.0 (0.3–3.6)
Unknown 9 (16%) 75 (13%) — —
Axillary lymph node status
Negative 24 (41%) 311 (54%) 1
a 1
a,e
Positive 31 (53%) 248 (43%) 1.6 (0.9–2.8) 1.6 (0.9–3.0)
Unknown 3 (5%) 16 (3%) — —
Histologic grade
1 19 (33%) 130 (23%) 1
a 1
a
2 17 (29%) 217 (38%) 0.5 (0.3–1.1) 0.5 (0.2–1.0)
3 17 (29%) 171 (30%) 0.7 (0.3–1.4) 0.6 (0.3–1.2)
Unknown 5 (9%) 57 (10%) — —
Oestrogen receptor status
Positive 43 (74%) 367 (64%) 1
a 1
a
Negative 11 (19%) 143 (25%) 0.7 (0.3–1.3) 0.6 (0.3–1.3)
Unknown 4 (7%) 65 (11%) — —
Bilateral breast cancer
No 53 (91.0%) 546 (95%) 1
a 1
a
Yes, synchronous 3 (5%) 9 (2%) 3.4 (0.9–13.1) 3.9 (1.0–15.8)
Yes, metachronous 2 (3%) 20 (4%) 1.0 (0.2–4.5) 1.0 (0.2–4.4)
OR¼odds ratio; CI¼confidence interval.
aReference category.
bAdjusted OR for age category was not adjusted for age.
cAdjusted OR for stage was not adjusted for stage.
dOR
for tumour size was adjusted for age and lymph node status (and not for stage).
eOR for lymph node status was adjusted for age and tumour size (and not for stage). **Po0.01.
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strong family history had less often early-stage disease at diagnosis
and more often locally advanced disease than early-onset patients
with no family history. The absence of association between a
positive family history and earlier detection of the disease has
previously been reported (Groenendijk et al, 2002; Madlensky
et al, 2005). One explanation could be that, compared to sporadic
cases, BRCA1/BRCA2-related breast cancers, as well as breast
cancers diagnosed in the context of a strong family history, are less
susceptible to be detected by mammography screening (Brekelmans
et al, 2001; Stoutjesdijk et al, 2001). Also, some of the high familial
risk patients might have had fast growing cancers, which became
symptomatic in between two screening interventions. Another
reason could be unawareness of the public and professionals on
the importance of a strong family history as a major risk factor for
breast cancer.
This study is the first one to investigate the impact of family
history on the management of early-onset breast cancer in a
population-based setting. Despite the limited number of
patients with a strong family history, we were able to demo-
nstrate important and significant differences in the management of
patients at high vs low familial risk. After adjustment for age, stage
at diagnosis, oestrogen receptor status and use of chemotherapy,
early-onset breast cancer patients with a high familial risk were
Table 3 Methods of detection and treatment of breast cancer according to family history
Familial risk
High familial
risk (n¼58)
Low familial risk
(n¼575)
Unadjusted OR
(95% CI)
Multi-adjusted
OR (95% CI)
Method of detection
Self examination 22 (38%) 213 (37%) 1
a 1
a,b
Surveillance 16 (28%) 132 (23%) 1.2 (0.6–2.3) 1.3 (0.7–2.8)
Symptoms 17 (29%) 203 (35%) 0.8 (0.4–1.6) 0.7 (0.4–1.4)
Fortuitous 3 (5%) 17 (3%) 1.7 (0.5–6.3) 1.8 (0.5–7.0)
Unknown 0 (0%) 10 (2%) — —
Locoregional treatment
Breast-conserving surgery 36 (62%) 338 (59%) 1
a 1
a,b
Mastectomy 14 (24%) 164 (29%) 0.8 (0.4–1.5) 0.7 (0.3–1.2)
Bilateral mastectomy 3 ( 5%) 6 (1%) 4.7 (1.1–19.6)* 4.2 (0.9–18.4)
Other 5 (9%) 67 (12%) 0.7 (0.3–1.9) 0.6 (0.2–1.7)
Chemotherapy
No 15 (26%) 201 (35%) 1
a 1
a,c
Yes 43 (74%) 374 (65%) 1.5 (0.8–2.8) 1.3 (0.6–2.7)
Hormonotherapy
No 25 (43%) 345 (60%) 1
a 1
a,d
Yes 33 (57%) 230 (40%) 2.0 (1.1–3.4)* 1.9 (1.1–3.4)*
OR¼odds ratio;
aReference category.
bAdjusted for age and stage at diagnosis.
cAdjusted for age, stage at diagnosis, locoregional treatment, oestrogen receptor status and use of
hormotherapy.
dAdjusted for age, stage at diagnosis, locoregional treatment, oestrogen receptor status and use of chemotherapy. *Po0.05.
Table 4 Use of systemic therapy according to lymph node status, oestrogen receptor status and familial risk
Systemic therapy
Any systemic therapy Anti-oestrogen therapy Chemotherapy Both
Risk category Yes No Yes No Yes No Yes No
N0 High risk (n¼24) 21 (88%) 3 (12%) 16 (67%) 8 (33%) 14 (58%) 10 (42%) 9 (38%) 15 (62%)
Low risk (n¼311) 202 (65%) 109 (35%) 120 (39%) 191 (61%) 142 (46%) 169 (54%) 60 (19%) 251 (81%)
w
2 test for heterogeneity 0.024 0.007 0.230 0.034
N+ High risk (n¼31) 29 (94%) 2 (6%) 17 (55%) 14 (45%) 28 (90%) 3 (10%) 16 (52%) 8 (48%)
Low risk (n¼248) 231 (93%) 17 (7%) 104 (42%) 144 (58%) 226 (91%) 22 (9%) 99 (40%) 149 (60%)
w
2 test for heterogeneity 0.933 0.172 0.882 0.011
ER+ High risk (n¼43) 40 (93%) 3 (7%) 32 (74%) 11 (26%) 33 (77%) 10 (23%) 25 (58%) 18 (42%)
Low risk (n¼367) 289 (79%) 78 (21%) 205 (56%) 162 (44%) 224 (61%) 143 (39%) 140 (38%) 227 (62%)
w
2 test for heterogeneity 0.026 0.020 0.044 0.011
ER  High risk (n¼11) 9 (82%) 2 (18%) 1 (9%) 10 (91%) 8 (73%) 3 (26%) 0 (0%) 11 (100%)
Low risk (n¼143) 115 (80%) 28 (20%) 16 (11%) 127 (89%) 114 (79%) 29 (21%) 15 (10%) 128 (90%)
w
2 test for heterogeneity 0.910 0.831 0.528 NA
N0¼no metastasis in axillary lymph nodes; N+¼metastasis in axillary lymph nodes; ER+¼oestrogen receptors status positive; ER ¼oestrogen receptor status negative;
NA¼not applicable. Note: 19 patients with unknown lymph node status (three high-risk and 16 low-risk patients) and 69 women with unknown oestrogen receptors status
(four high-risk and 65 low-risk patients) were not included in this table.
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stwice as likely to be treated with systemic therapy, especially for
lymph node-negative and for oestrogen receptor-positive disease.
This study gives no insight into the reasons why patients at high
familial risk received more frequently systemic treatments. One
can hypothesise that breast cancer occurring in the context of a
strong family history may be considered as a more aggressive
disease. Although some clear histopathological differences have
been observed between BRCA1-related breast cancer and sporadic
cases (more high grade, oestrogen receptor-negative and p53-
positive tumours in BRCA1 mutation carriers), this has not been
demonstrated for familial cases of breast cancer (Breast Cancer
Linkage Consortium, 1997; van de Vijver, 1999). We did not
observe a significant difference in proportion of grade 3 or
oestrogen receptor-negative tumours between women at high vs
low familial risk, but the proportion of stage III disease was
significantly higher. However, differences in systemic treatment
persisted after adjustment for stage.
Another explanation for the more complete treatment of women
at high familial risk could be the patient’s attitude towards her
disease and treatment options. Women at high familial risk have
usually witnessed the disease in family members and may even
have lost a close relative from breast cancer. Such a personal
experience might result in a willingness to accept or demand more
aggressive or complete therapy. Until now, however, there are no
solid data to confirm differences in attitude towards breast cancer
treatment among women at high vs low familial risk.
Finally, one can hypothesise that treating physicians consider
women with a strong family history at increased risk for local
recurrence, contralateral disease and, ultimately, death from breast
cancer compared to patients without a family history. By giving
systemic therapy or proposing the option of preventive bilateral
mastectomy, physicians expect to reduce these risks. In the 1990s,
several multicentric trials were initiated to determine the efficacy
of tamoxifen as a chemopreventive drug to reduce breast cancer
incidence among moderate- and high-risk women (Jordan, 1997;
Osborne, 1999; Cuzick et al, 2002). Although none of the Geneva
hospitals participated in these trials, the publicity around this
topic might have influenced the attitude of the local physicians.
This does not explain the increased use of chemotherapy, but may
have increased the use of hormonotherapy among high familial
risk patients.
Differences in use of systemic therapy between young women
with a strong family history vs those without affected relatives can
have important impact on breast cancer mortality. Since the late
1990s, several studies have demonstrated the importance of
adjuvant chemotherapy among young breast cancer patients by
showing that the unfavourable impact of young age on breast
cancer survival is valid only among patients treated without
chemotherapy, and that among women treated with chemotherapy,
young age is no longer an independent prognostic risk factor
(Greenberg et al, 1985; Kroman et al, 2000; Rapiti et al, 2005). In
this study, we show that young breast cancer patients without
axillary lymph node involvement were more likely to be treated
with chemotherapy, hormonotherapy or both, if they had a strong
family history of breast or ovarian cancer. If, in other series as well,
more complete treatment would have been given to high familial
risk patients, the impact of a strong family history on survival
could have been underestimated. This could explain why, in some
studies, women with a strong family history survive better than
women without affected relatives.
To our knowledge, it is the first time that use of systemic
therapy was accounted for while estimating the impact of a strong
family history on survival after early-onset breast cancer. Despite
the absence of statistically significant results, due to the low power
of our study, our data suggest that accounting for treatment is
important. Especially in the subgroup of women who did not
receive chemotherapy, the presence of a positive family history
appeared to increase the risk to die of breast cancer. This
observation is substantiated by two earlier studies among
Ashkenazi Jewish breast cancer patients. In these studies, BRCA1
status was a strong predictor of breast cancer survival only
among women who did not receive chemotherapy, while among
women who received chemotherapy it was not (Goffin et al, 2003;
Robson et al, 2004).
The results of our study also suggest that among very young
women (under 41 years of age at diagnosis), a strong family history
might have a negative impact on breast cancer survival. These
results are substantiated by a recent study from investigators at the
MD Anderson Cancer Center, showing that among very young
breast cancer patients (p35 years), a family history of ovarian
cancer strongly impaired disease-free and overall survival
(Gonzalez-Angulo et al, 2005). Nevertheless, the low number of
cases prevented us from drawing definite conclusions and the
results should be used only to generate hypotheses. A possible
explanation might be that the proportion of BRCA1 carriers is
higher among very young women at high familial risk. As BRCA1-
related tumours exhibit poor prognostic characteristics (negative
oestrogen receptor status and high grade) and have often been
shown to be associated with impaired survival rates (Moller et al,
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Figure 1 Breast cancer-specific survival for young women (p50 years)
at highly increased familial risk and women at low familial risk.
Table 5 Impact of familial risk on breast cancer mortality according to
age at diagnosis and use of chemotherapy
N
N
deaths
Unadjusted
HR
Multi adjusted hazard
ratio (95% CI)
a
41–50 years
Low risk 441 55 1
b 1
b
High risk 48 5 0.9 (0.3–2.1) 1.0 (0.4–2.6)
o41 years
Low risk 144 18 1
b 1
b
High risk 10 2 2.1 (0.5–9.1) 4.0 (0.8–19.7)
Chemotherapy
Low risk 374 54 1
b 1
b
High risk 43 5 0.9 (0.4–2.2) 1.0 (0.4–2.6)
No chemotherapy
Low risk 201 19 1
b 1
b
High risk 15 2 1.5 (0.3–6.4) 2.7 (0.6–12.5)
aAdjusted for socioeconomic status, stage, grade, oestrogen receptor status,
locoregional treatment, chemotherapy and hormonotherapy.
bReference category.
Family history and early-onset breast cancer
HM Verkooijen et al
236
British Journal of Cancer (2006) 94(2), 231–238 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s2002), this could explain the negative impact of strong family
history in the subgroup of very young women. However, in our
group of patients, tumours of the ‘younger’ patients with a strong
family history were neither of higher grade, nor more often
oestrogen receptor negative than the tumours of the ‘older’
patients with a strong family history. Therefore, the effect of a
strong family history on survival of very young women needs
further investigation.
Based on this study, we conclude that guidelines on screening
and management of young women at high familial risk are needed.
By better informing the public and primary care physicians on the
importance of family history, it should be possible to increase the
number of women identified as high risk of developing breast
cancer and to propose to these women specific screening and
prevention protocols. Finally, additional research is needed to
confirm if a strong family history of breast cancer impairs survival
of very young patients and those treated without chemotherapy.
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